Use of antibody or its derivative for preparation of medicament for passive immunization of individual for preventing and/or treating allergic reactions in individual caused by exposure to birch pollen allergen

摘要

Use of an antibody or its derivative for preparation of a medicament for passive immunization of an individual for preventing and/or treating allergic reactions in the individual caused by exposure to a birch pollen allergen. The antibody is capable of binding to Bet v 1 fragment comprising amino acid residues at position 30-59 of a defined sequence of 31 amino acids (SEQ ID No. 1) given in the specification or amino acid residues at position 75- 104 of a defined sequence of 31 amino acids (SEQ ID No. 2) given in the specification. Independent claims are included for the following: (1) antibody or its derivative capable of binding to a fragment of Bet v 1, comprising the fragment of Bet v 1 including an amino acid residues at position 30-59 of SEQ ID No. 1 or amino acid residues at position 75-104 of SEQ ID No. 2; (2) vaccine formulation comprising the above antibody; (3) nucleic acid molecule comprising a base sequence of SEQ ID No. 3-298 as provided in figure 2 given in the patent specification; (4) polypeptide coded by the above nucleic acid molecule; and (5) antibody or its fragment comprising the above polypeptide. ACTIVITY : Antiallergic. In a test for measuring inhibition of mouse immunoglobulin (Ig)E binding to rBet v 1 using murine model, the rBet v 1-specific IgG antibodies exhibited inhibition rate of 54.6% compared to control (1%). MECHANISM OF ACTION : Vaccine.